Literature DB >> 3342577

Osteomalacia as a very late manifestation of primary hyperparathyroidism.

F S Kaplan1, S R Soffer, M D Fallon, J G Haddad, M Dalinka, E C Raffensperger.   

Abstract

An 86-year-old woman with a history of treated hyperthyroidism and a 20-year history of untreated primary hyperparathyroidism developed generalized bone pain and a pseudofracture of the midshaft of the left femur. Laboratory examinations revealed elevated serum calcium, alkaline phosphatase, and C-terminal parathyroid hormone levels. Serum inorganic phosphate was below normal and 25-hydroxyvitamin D levels were low-normal. An undecalcified transiliac bone biopsy specimen following tetracycline double labeling revealed osteomalacia and osteitis fibrosa. Following treatment with vitamin D and phosphate, the serum inorganic phosphate level rose to normal. There was a decrease in bone pain, and the pseudofracture healed. However, the serum calcium, alkaline phosphatase, and C-terminal parathyroid hormone levels remained elevated. Longstanding primary hyperparathyroidism causes chronic hypophosphatemia and may lead to osteomalacia. Osteomalacia and its consequences may be part of the spectrum of bone disease seen in patients with longstanding primary hyperparathyroidism.

Entities:  

Mesh:

Year:  1988        PMID: 3342577

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  The cause of maintained hypercalciuria after the surgical cure of primary hyperparathyroidism is a defect in renal calcium reabsorption.

Authors:  M L Farias; A G Delgado; D Rosenthal; J G Vieira; T Kasamatsu; M J Lazarevitch; M F Pereira; M B Lima
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

2.  An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation.

Authors:  Moez Gribaa; Mohamed Younes; Yosra Bouyacoub; Wided Korbaa; Ilhem Ben Charfeddine; Mongi Touzi; Labiba Adala; Ons Mamay; Naceur Bergaoui; Ali Saad
Journal:  J Bone Miner Metab       Date:  2009-08-05       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.